| Name | Title | Contact Details |
|---|
Waldorf Technik Inc. is a Saint Charles, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Anthelio Healthcare Solutions Inc. is much more than a healthcare IT company. We are a single source provider of world-class technology solutions for the healthcare industry with a 15-year history of excellence. Our innovative services and products make it easier for our customers to do what they do best – deliver outstanding patient care. Our company was built on the foundation that healthcare is our only business, uniquely positioning us as one of the very few companies who focus solely on the needs of our healthcare customers and their patients. We take great pride in maintaining the highest levels of client satisfaction for the hundreds of U.S. hospitals and healthcare providers we serve. We strive to provide a unique customer experience by proactively anticipating our customers' needs and pain points and by delivering fast, flexible and bold solutions. In an ever-evolving healthcare industry, we are at the forefront of delivering cutting-edge, scalable technologies and solutions that respond to the market's needs while maintaining sustainable value to our customers.
Cornell Scott-Hill Health Center is one of the leading companies in Healthcare, Pharmaceuticals, and Biotech industry. Cornell Scott-Hill Health Center is based in New Haven, CT. You can find more information on Cornell Scott-Hill Health Center at www.hillhealthcenter.com
Foresee is a Taiwan and US-based biopharmaceutical company listed on the Taipei Exchange (6576.TWO). Foresee`s R&D efforts are focused in two key areas, namely its unique stabilized injectable formulation (SIF) depot delivery technology with derived drug products targeting specialty markets, and secondly its transformative preclinical and clinical first-in-class NCE programs targeting rare and severe disease areas with high unmet needs. Foresee`s product portfolio includes late stage and early stage programs. CAMCEVI® 42 mg is now approved in the U.S. and under regulatory review in the EU. Additionally, U.S. and EU regulatory submissions are in preparation for CAMCEVI® 21 mg. FP-025 – a highly selective oral MMP-12 inhibitor targeting inflammatory and fibrotic diseases, currently in Phase 2/3 studies, including a Phase 2/3 study for COVID-19 virus-induced acute respiratory distress syndrome (ARDS). FP-045 – a highly selective oral small molecule allosteric activator of ALDH2, a mitochondrial enzyme, for which a Phase 1b/2 study is currently planned for Fanconi Anemia.
AdvanSource Biomaterials Corporation is a Wilmington, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.